(Created) Tag: Visual edit |
m (Applied stub template.) Tag: Visual edit |
||
| Line 1: | Line 1: | ||
{{Message box/Stub}} | |||
'''Intellectual property''' is an intangible form of [[private property]] under [[capitalism]] that includes [[copyright]] and patents. Patents on technology cause [[Monopoly|monopolization]] and increase the prices of prescription drugs by over 300%, from under $105 billion per year in the U.S. to over $420 billion.<ref>{{Web citation|author=Martin Hart-Landsberg|newspaper=[[Monthly Review]]|title=Corporate concentration, intellectual property rights, and U.S. public policy|date=2018-05-11|url=https://mronline.org/2018/11/05/corporate-concentration-intellectual-property-rights-and-u-s-public-policy/|archive-url=https://web.archive.org/web/20211017072147/https://mronline.org/2018/11/05/corporate-concentration-intellectual-property-rights-and-u-s-public-policy/|archive-date=2021-10-17|retrieved=2022-09-25}}</ref> | '''Intellectual property''' is an intangible form of [[private property]] under [[capitalism]] that includes [[copyright]] and patents. Patents on technology cause [[Monopoly|monopolization]] and increase the prices of prescription drugs by over 300%, from under $105 billion per year in the U.S. to over $420 billion.<ref>{{Web citation|author=Martin Hart-Landsberg|newspaper=[[Monthly Review]]|title=Corporate concentration, intellectual property rights, and U.S. public policy|date=2018-05-11|url=https://mronline.org/2018/11/05/corporate-concentration-intellectual-property-rights-and-u-s-public-policy/|archive-url=https://web.archive.org/web/20211017072147/https://mronline.org/2018/11/05/corporate-concentration-intellectual-property-rights-and-u-s-public-policy/|archive-date=2021-10-17|retrieved=2022-09-25}}</ref> | ||
Revision as of 23:20, 6 November 2022
 | This article is a stub. You can help improve this article by editing it. |
Intellectual property is an intangible form of private property under capitalism that includes copyright and patents. Patents on technology cause monopolization and increase the prices of prescription drugs by over 300%, from under $105 billion per year in the U.S. to over $420 billion.[1]
References
- ↑ Martin Hart-Landsberg (2018-05-11). "Corporate concentration, intellectual property rights, and U.S. public policy" Monthly Review. Archived from the original on 2021-10-17. Retrieved 2022-09-25.